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The mechanism of action of cannabidiol (CBD), the main non-psychotropic component
of Cannabis sativa L., is not completely understood. First assumed that the compound
was acting via cannabinoid CB2 receptors (CB2Rs) it is now suggested that it interacts
with non-cannabinoid G-protein-coupled receptors (GPCRs); however, CBD does not
bind with high affinity to the orthosteric site of any GPCR. To search for alternative
explanations, we tested CBD as a potential allosteric ligand of CB2R. Radioligand and
non-radioactive homogeneous binding, intracellular cAMP determination and ERK1/2
phosphorylation assays were undertaken in heterologous systems expressing the
human version of CB2R. Using membrane preparations from CB2R-expressing HEK-
293T (human embryonic kidney 293T) cells, we confirmed that CBD does not bind
with high affinity to the orthosteric site of the human CB2R where the synthetic
cannabinoid, [3H]-WIN 55,212-2, binds. CBD was, however, able to produce minor
but consistent reduction in the homogeneous binding assays in living cells using the
fluorophore-conjugated CB2R-selective compound, CM-157. The effect on binding to
CB2R-expressing living cells was different to that exerted by the orthosteric antagonist,
SR144528, which decreased the maximum binding without changing the KD. CBD at
nanomolar concentrations was also able to significantly reduce the effect of the selective
CB2R agonist, JWH133, on forskolin-induced intracellular cAMP levels and on activation
of the MAP kinase pathway. These results may help to understand CBD mode of action
and may serve to revisit its therapeutic possibilities.
Keywords: endocannabinoid, allosterism, G-protein-coupled receptor, phytocannabinoids, SR144528,
irreversible, TR-FRET
Abbreviations: AEA, anandamide; 2-AG, 2-arachidonyl glycerol; CBD, cannabidiol; CB1R, cannabinoid receptor subtype 1;
CB2R, cannabinoid receptor subtype 2; CNS, central nervous system; GPCR, G-protein-coupled-receptor; HTRF,
homogenous time-resolved fluorescence resonance energy transfer; 19-THC, 19-tetrahydrocannabinol; TR-FRET, time-
resolved fluorescence resonance energy transfer.
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INTRODUCTION
The endocannabinoid system consists of two compounds
with amphipathic structure, 2-arachidonyl glycerol (2-AG) and
anandamide (AEA), the enzymes that produce and degrade them,
and two cannabinoid, CB1 and CB2, receptors (see Lu and
MacKie, 2016 and references therein). Recent evidence presents
the endocannabinoid system as one of the most relevant in
mammals for homeostatic control of energy expenditure and
temperature, and for regulating innate and acquired immunity
and neural transmission. Cannabinoid receptors belong to the
superfamily of G-protein-coupled receptors (GPCRs) and are
reportedly coupled to the heterotrimeric Gi protein1, i.e., their
activation leads to a decrease in the intracellular level of a
second messenger, cAMP. Although CB1 receptors (CB1Rs)
are mainly located in neurons of the central nervous system
(CNS), their expression in glia has been described (Stella,
2010; Bilkei-Gorzo, 2012). In fact, CB1Rs are considered to
be the most abundant GPCRs in the CNS and the targets of
the 19-tetrahydrocannabinol (19-THC), the main psychotropic
component of Cannabis sativa L. CB2 receptor (CB2R), which
soon after its identification was considered a prototypic
peripheral receptor, is also expressed in the CNS, both in
glia (Zhang et al., 2003; Cabral and Marciano-Cabral, 2005;
Fernández-Ruiz et al., 2007) and neurons of some specific
brain regions such as cerebellum or globus pallidus (Lanciego
et al., 2011; Sierra et al., 2015). Heteromerization of CB1R/CB2R
in the brain is a well-accepted phenomenon that further
diversifies the physiological actions of endo- and exogenous
cannabinoids (Callén et al., 2012; Sierra et al., 2015). Although
physiological relevance of this heteromer expression is not fully
understood, evidence suggests potential in CNS-related drug
discovery.
Apart from heteromerization, drug discovery efforts for
cannabinoid receptors also involve the use of allosteric
cannabinoid ligands. Whereas cannabinoids interact with
the orthosteric receptor site, allosteric modulators bind to
a topographically distinct binding site modifying receptor
conformation and leading to novel properties and modes of
action (Conn et al., 2009). In fact, allosteric modulators can
impact on the affinity of the orthosteric binding pocket and also
in the intracellular signaling responses, in either a positive or
negative direction. To date, a number of allosteric cannabinoid
receptor modulators have been reported for CB1R, e.g., lipoxin
A4, ORG27569, PSNCBAM-1 or cannabidiol (CBD) (Pamplona
et al., 2012; Laprairie et al., 2015; Morales et al., 2016).
CBD, the main non-psychoactive phytocannabinoid, exerts
a wide range of cellular effects through the endocannabinoid
system, as was indicated in a systematic review in 2015
(McPartland et al., 2015). However, its mode of action is far
from being understood. In some in vitro assays, CBD action has
been linked to CB2Rs activation because some in vivo effects
were blocked by the administration of a CB2R antagonist. Thus,
Ignatowska-Jankowska et al. (2011), using AM630 as antagonist,
reported that the weight gain-reducing effect of CBD apparently
1www.guidetopharmacology.org
involved CB2Rs. In addition, the well-substantiated protective
role of CBD in newborn hypoxia-ischemia correlates with CB2R
expression (Castillo et al., 2007; Alvarez et al., 2008; Lafuente
et al., 2011; Pazos et al., 2013). In other in vitro assays, CBD
was shown as a high potency antagonist of CB2R expressed in
CHO cells (Thomas et al., 2009). Nevertheless, radioligand and/or
GTPgammaS binding assays indicate that the compound does
not bind with high affinity to either rat or human CB2Rs (Hanus
et al., 2005; Pertwee, 2008; McPartland et al., 2009). At present,
the idea that CBD actions are mediated by binding to serotonin 5-
HT1A receptors is favored. For instance, CBD affords protection
against oxygen-glucose deprivation in a model of the blood–brain
barrier by a mechanism involving 5-HT1A and PPARγ receptors
(Hind et al., 2016). Further behavioral studies also suggest that
CBD may act via 5-HT1A receptors (Russo et al., 2005; Alves
et al., 2010; Magen et al., 2010; Rock et al., 2012; Espejo-Porras
et al., 2013; Sartim et al., 2016). Such assumption is intriguing as
the reported affinity of CBD binding to these serotonin receptors
does not lie within the nanomolar high affinity range (Russo
et al., 2005). More recently, some authors open new avenues
in the therapeutic use of this phytocannabinoid. Thus, they
seem to demonstrate that CBD was able to reduce the effect of
2-AG and 19-THC on CB1R internalization and PLCβ3 and
ERK1/2 phosphorylation, proposing that CBD may act as a
negative allosteric modulator of these receptors (Laprairie et al.,
2015).
The aim of this work was to search for the possibility that
CBD acts as an allosteric ligand of CB2R by checking whether
it is able to modulate the binding and functional effect of CB2R
agonists.
MATERIALS AND METHODS
Materials and Reagents
For radioligand binding assays, [3H]-(R)-(+)-[2,3-dihydro-5
-methyl-3-(4-morpholinyl methyl)pyrrolo[1,2,3-de]-1,4-benzo-
xazin-6-yl]-1-naphthalenylmethanone ([3H]-WIN 55,212-2) was
purchased from PerkinElmer (Wellesley, MA, United States).
CBD, WIN 55,212-2 mesylate and SR144528 were obtained from
Tocris Bioscience (Bristol, United Kingdom). THC was obtained
from THC Pharm (Frankfurt, Germany).
For non-radioactive binding assays, the Tag-lite labeling
medium (TLB) was obtained from Cisbio Bioassays (LABMED,
Cisbio Assays, Codolet, France). The Tb derivative of O6-benzyl-
guanine was synthesized by Cisbio Bioassays and is
commercialized as SNAP-Lumi4-Tb (SSNPTBC, Cisbio Assays,
Codolet, France). CB2R agonist, 3-[[4-[2-tert-butyl-1-(tetra-
hydropyran-4-ylmethyl)benzimidazol-5-yl]sulfonyl-2-pyridyl]-
oxy]propan-1-amine (CM-157), conjugated to red-naltrexone
fluorescent probe (red CB2R ligand) was developed by Cisbio
Bioassays. The unlabeled compound was synthesized as described
in Martínez-Pinilla et al. (2016) based on the information given
in the WO2008003665 patent and in Verbist et al. (2008).
Stock solutions were prepared in DMSO. Aliquots of these
stock solutions were kept frozen at −20◦C until use. The
plasmid encoding for the SNAP-tagged human CB2R used
Frontiers in Pharmacology | www.frontiersin.org 2 October 2017 | Volume 8 | Article 744
fphar-08-00744 October 19, 2017 Time: 15:18 # 3
Martínez-Pinilla et al. CBD Allosterism in CB2 Receptors
for transient transfection was obtained from Cisbio Bioassays
(PSNAP-CB2, Cisbio Assays, Codolet, France). The white opaque
384-well plates were obtained from PerkinElmer (Wellesley, MA,
United States).
Radioligand Binding Assays
Cell Culture and Membrane Preparation
CHO cells stably expressing human CB2R (CHO-CB2R)
(PerkinElmer, United States) were grown adherently and
maintained in Ham’s F12 medium containing 10% heat-
inactivated fetal bovine serum (FBS), 100 units/mL
penicillin/streptomycin and 0.4 mg/mL geneticin (G418) at 37◦C
in 5% CO2 humid atmosphere.
For membrane isolation, culture medium was removed and
cells were washed with phosphate-buffered saline (PBS) and
scraped off in ice-cold hypotonic buffer (5 mM Tris–HCl, 2 mM
EDTA, pH 7.4). The cell suspension was homogenized with a
Polytron and then centrifuged for 30 min at 40,000 × g. The
membrane pellet was suspended in 50 mM Tris–HCl buffer (pH
7.4) containing 1 mM EDTA, 5 mM MgCl2, 0.5 mg/mL bovine
serum albumin (BSA).
Saturation Binding Experiments
[3H]-WIN 55,212-2 saturation binding experiments (specific
activity 48 Ci/mmol, PerkinElmer) were performed incubating
different concentrations of the radioligand (0.2–40 nM) in
binding buffer (50 mM Tris–HCl, pH 7.4, 1 mM EDTA, 5 mM
MgCl2) with membranes from CHO cells stably expressing
the human CB2R (10 µg per sample) at 30◦C. Non-specific
binding was determined in the presence of 1 µM WIN 55,212-2.
At the end of the incubation period (60 min) bound and
free radioactivity were separated in a Brandel cell harvester
(Brandel Instruments) by filtering the assay mixture through
Whatman GF/B glass fiber filters. The filter-bound radioactivity
was counted using a Packard Tri Carb 2810 TR scintillation
counter (PerkinElmer, Wellesley, MA, United States).
Association Binding Experiments
Association binding experiments for [3H]-WIN 55,212-2 were
performed incubating three different concentrations (0.8, 1.6, and
3.2 nM) of the radioligand in binding buffer (50 mM Tris–HCl,
pH 7.4, 1 mM EDTA, 5 mM MgCl2) with human CHO-CB2R
cell membranes at 30◦C. Non-specific binding was determined in
the presence of 1 µM WIN 55,212-2. Free and bound radioligand
were separated through filtration at multiple time points (from 1
to 50 min) to construct association kinetic curves.
Dissociation Binding Experiments
The dissociation rate of [3H]-WIN 55,212-2 was determined by
allowing 3 nM radioligand to reach equilibrium with human
CHO-CB2R cell membranes at 30◦C for 60 min. To start
dissociation, WIN 55,212-2 (10 µM final concentration) was
added in order to occupy binding sites as they became available,
thereby preventing re-association. The amount of radioactivity
that remained bound to the receptor was determined by filtration
harvesting and scintillation counting at different time points
(from 0 to 50 min).
Competition Binding Experiments
Competition binding experiments were performed incubating
3 nM [3H]-WIN 55,212-2 and different concentrations of the
tested compounds with membranes obtained from CHO-CB2R
cells (10 µg protein per sample) for 60 min at 30◦C. Non-
specific binding was determined in the presence of 1 µM WIN
55,212-2. Bound and free radioactivity were separated by filtering
the assay mixture through Whatman GF/B glass fiber filters
using a Brandel cell harvester. The filter-bound radioactivity was
counted using a Packard Tri Carb 2810 TR scintillation counter
(PerkinElmer).
Non-radioligand Binding Assays
Cell Line Cultures and Transfection
Human embryonic kidney 293T (HEK-293T) cells were grown
in DMEM supplemented with 2 mM L-glutamine, 1 mM sodium
pyruvate, 100 units/mL penicillin/streptomycin, and 5% (v/v)
FBS (all supplements were from Invitrogen, Paisley, Scotland,
United Kingdom). Cells were maintained at 37◦C in a humidified
atmosphere of 5% CO2 and were passaged, with enzyme-free cell
dissociation buffer (13151-014, Gibco R©, Thermo Fisher Scientific,
Waltham, MA, United States), when they were 80–90% confluent,
i.e., approximately twice a week.
For fluorescent ligand-binding assays, HEK-293T cells
growing in 25-cm2 flasks were transiently transfected with the
SNAP-CB2R plasmid cloned in pcDNA3.1 by the Lipofectamine
2000 method (11668-019, Invitrogen, Thermo Fisher Scientific,
Waltham, MA, United States). When reaching 60% confluence,
cell medium was removed and replaced by 4 mL of fresh
medium. In parallel, a transfection mix containing 8 µg of
plasmid, 20 µL of Lipofectamine 2000, and 1 mL of Opti-MEM
without serum (51985-026, Gibco R©, Thermo Fisher Scientific,
Waltham, MA, United States) final volume was incubated for
20 min at room temperature prior to being added on cells. The
transfected-cell culture flask was incubated at 37◦C under 5%
CO2 for 24 h.
Labeling of Cells Expressing SNAP-Tagged CB2R
Cell culture medium was removed from the 25-cm2 flask and
100 nM SNAP-Lumi4-Tb, previously diluted in 3 mL of TLB
1×, was added to the flask and incubated for 1 h at 37◦C under
5% CO2 atmosphere in a cell incubator. After that, cells were
washed four times with 2 mL of TLB 1× to remove the excess
of SNAP-Lumi4-Tb, detached with enzyme-free cell dissociation
buffer, centrifuged 5 min at 1,500 rpm and collected in 1 mL of
TLB 1×. Tag-lite-based binding assays were performed 24 h after
transfection. Densities from 2,500 to 3,000 cells per well were
used to carry out binding assays in suspension in white opaque
384-well plates.
Competition and Saturation Binding Assays
For competition binding assay, red CB2R ligand (labeled CM-
157) and CBD were diluted in TLB 1×. HEK-293T cells
transiently expressing Tb-labeled SNAP-CB2R were incubated
with 100 nM red CB2R ligand, in the presence of increasing
concentrations (0–10 µM range) of CBD. In plates containing
10 µL of labeled cells, 5 µL of TLB 1× or 5 µL of CBD was added
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FIGURE 1 | Saturation curves from radioligand binding. Saturation curve (A)
and relative Scatchard plot (B) of [3H]-WIN 55,212-2 binding on membranes
from CHO cells stably expressing human CB2R. Data are expressed as the
mean ± SEM of three independent experiments performed in duplicate.
prior to the addition of 5 µL of fluorescent ligand. Plates were
then incubated for at least 2 h at room temperature before signal
detection.
Saturation binding experiments were performed by incubating
HEK-293T cells transiently expressing Tb-labeled SNAP-CB2R
with increasing concentrations of the red CB2R ligand (range,
0–300 nM final) in TLB 1×. For each concentration, non-specific
binding was determined by adding 100 µM unlabeled CB2R
ligand. In the plates containing 10 µL labeled cells, 5 µL of
100 µM unlabeled CB2R ligand or TLB 1× was added, followed
by the addition of 5 µL of increasing concentrations of the red
CB2R ligand. Plates were incubated for 2 h at room temperature
before signal reading.
Signal was detected using an EnVision microplate reader
(PerkinElmer, Waltham, MA, United States) equipped with a
FRET optic module allowing donor excitation at 337 nm and
signal collection at both 665 and 620 nm. A frequency of 10
flashes/well was selected for the xenon flash lamp excitation.
The signal was collected at both 665 and 620 nm using the
following time-resolved settings: delay, 150 µs; integration time,
500 µs. HTRF ratios were obtained by dividing the acceptor
signal (665 nm) by the donor signal (620 nm) and multiplying
this value by 10,000. The 10,000-multiplying factor is used solely
for the purpose of easier data handling.
Data Analysis
Data were then analyzed using Prism 6 (GraphPad Software,
Inc., San Diego, CA, United States). KD values were obtained
from saturation curves of the specific binding. Specific binding
was determined by subtracting the non-specific HTRF ratio
from the total HTRF ratio. KD and Bmax values in saturations
experiments were calculated assuming one binding site in
monomeric receptor. Unlike in radioligand binding assays,
Bmax values obtained from HTRF data do not reflect absolute
values of receptor binding sites; they are, however, useful
for comparison purposes. Finally, Ki values were determined
according to the Cheng and Prusoff equation (Cheng, 2001).
Signal-to-background (S/B ratio) calculations were performed by
dividing the mean of the maximum value (µmax) by that of the
minimum value (µmin) obtained from the sigmoid fits.
cAMP Determination
Two hours before initiating the experiment, growth medium
was replaced by serum-free DMEM. Then, HEK-293T cells
transiently expressing CB2R or GPR55 were detached and
FIGURE 2 | Competition curves in radioligand- and HTRF-based assays. (A) Competition curves of specific 3 nM [3H]-WIN 55,212-2 binding by unlabeled
(0–10 µM) WIN 55,212-2, CBD and THC. (B) Competition curve of specific binding of 100 nM red CB2R ligand with increasing concentrations of CBD (0–10 µM)
measured by HTRF. Data represent the mean ± SEM of a representative experiment (n = 4). HTRF ratio = (665 nm acceptor signal/620 nm donor signal) × 10,000.
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FIGURE 3 | Saturation curves measured by HTRF. Saturation binding experiments of fluorescent CB2R ligand (CM-157) in HEK-293T cells transiently transfected
with SNAP-CB2R in the absence or presence of 10 nM (squares) or 100 nM (triangles) CBD (A), or in the absence or presence of 10 nM (squares) or 100 nM
(triangles) SR144528 (B). Specific binding signals were calculated by subtracting the non-specific signal determined in the presence of 100 µM unlabeled CB2R
ligand. Data represent the mean ± SEM of a representative experiment (n = 4). HTRF ratio = (665 nm acceptor signal/620 nm donor signal) × 10,000.
TABLE 1 | Red CB2R ligand (CM-157) binding parameters, in the absence and
presence of CBD. Data represent the mean ± SEM of five independent
experiments performed in quadruplicate.
Condition KD (nM) Bmax (RU)a,b
Red CB2R ligand 60 ± 10 3,480 ± 210
Red CB2R ligand + 10 nM CBD 82 ± 28 3,060 ± 360
Red CB2R ligand + 100 nM CBD 160 ± 20∗ 3,380 ± 210
aRU, relative unit. bBmax parameter does not indicate the actual level of binding
sites, but it may be used for comparative purposes. ∗Significant differences
analyzed by one-way ANOVA and Bonferroni’s multiple comparison post hoc tests
(∗p < 0.05 versus absence of CBD).
resuspended in growing medium containing 50 µM zardaverine
and plated in 384-well microplates (2,500 cells/well), pretreated
(15 min) with the corresponding antagonists—or vehicle—and
stimulated with agonists (15 min) before adding 0.5 µM forskolin
or vehicle. Readings were performed after 15 min of incubation
at 25◦C. HTRF measures were performed using the Lance
Ultra cAMP kit (PerkinElmer, Waltham, MA, United States).
Fluorescence at 665 nm was analyzed on a PHERAstar Flagship
microplate reader equipped with an HTRF optical module (BMG
Lab Technologies, Offenburg, Germany).
ERK1/2 Phosphorylation
To determine ERK1/2 phosphorylation, 40,000 HEK-293T-CB2R
cells/well were plated in transparent Deltalab 96-well microplates
and kept at the incubator for 24 h. Two to four hours before
the experiment, the medium was replaced by serum-free DMEM.
Then, cells were treated with 100 nM JWH133 and increasing
concentrations of CBD in serum-free medium at 25◦C for
7 min. Cells were then washed twice with cold PBS before
addition of lysis buffer (20 min treatment). Ten microliters
of each supernatant were placed in white ProxiPlate 384-well
microplates and ERK1/2 phosphorylation was determined
using AlphaScreen R©SureFire R© kit (PerkinElmer) following the
instructions of the supplier and using an EnSpire R© Multimode
Plate Reader (PerkinElmer, Waltham, MA, United States).
Statistical Analysis
The data in graphs are the mean ± SEM. Statistical analysis was
performed with SPSS 18.0 software. The test of Kolmogorov–
Smirnov with the correction of Lilliefors was used to evaluate
normal distribution and the test of Levene to evaluate the
homogeneity of variance. Significance was analyzed by one-
way ANOVA, followed by Bonferroni’s multiple comparison
post hoc test. Significant differences were considered when
p < 0.05.
RESULTS
Radioligand-Based Assays of Agonist
Binding to Human CB2R Expressed in
Isolated Membranes
The effect of CBD on agonist binding to CB2R was first tested
using a classical radioligand-binding assay and membranes
isolated from CHO cells stably expressing human CB2R
and incubated with [3H]-WIN 55,212-2. Data obtained from
binding isotherms using increasing WIN 55,212-2 concentrations
lead to a monophasic saturation curve with a KD value
of 3.4 ± 0.2 nM (Figures 1A,B), which fits with the
values reported in the literature (McPartland et al., 2009).
Kinetic experiments of association of [3H]-WIN 55,212-2
(Supplementary Figure 1A) and its dissociation by excess
unlabeled WIN 55,212-2 (Supplementary Figure 1B) showed kon
and koff values whose quotient provides an equilibrium constant
that is in agreement with the KD value calculated from saturation
data.
Competition and Saturation Assays in
the Presence of CBD
Competition of 3 nM [3H]-WIN 55,212-2 with increasing
concentrations of the “cold” compound led to a Ki value of
3.6 ± 0.3 nM, well in agreement with the KD (Figure 2A).
The Ki value, when CBD was used as competitor, was in the
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FIGURE 4 | Dose-response effect of CBD on cAMP levels. HEK-293T cells were transiently transfected with cDNA encoding for human CB2 (A,B) or GPR55 (C,D)
receptors. The effect of CBD on the decrease by JWH133 of forskolin-induced cAMP levels is displayed as a dose-response curve (B). Cells were treated (15 min)
with different concentrations of CBD in the absence or presence of 100 nM JWH133, a selective CB2R agonist and, finally, with 0.5 µM forskolin (15 min).
Agonist-induced reduction in cAMP was 31 ± 4 and data (mean ± SEM) are given in percentage of the 500 nM forskolin-induced cAMP concentration. Significant
differences were analyzed on data from seven different experiments; one-way ANOVA and Bonferroni’s multiple comparison post hoc test were used for statistical
analysis (F4,71 = 15, p < 0.001) (∗∗p < 0.01, ∗∗∗p < 0.001, versus 0 nM CBD treatment).
micromolar range (4.2 ± 0.3 µM). The same phenomenon
was observed with increasing concentrations of THC, Ki
value of 3.3 ± 0.2 µM (Figure 2A). Competition curves
in radioligand binding assays were clearly monophasic, i.e.,
no significant effect was observed at submicromolar CBD
concentrations.
Similar competition experiments were performed using
100 nM of a fluorescent CB2R agonist and a recently described
homogeneous non-radioactive method performed in living cells
expressing the human version of the receptor (details in
Martínez-Pinilla et al., 2016). Competition of binding to the
orthosteric center of the fluorescent agonist by CBD was partial
but consistent, occurring at low nanomolar CBD concentrations
(circa 25% reduction and IC50 in the 2–8 nM range) (Figure 2B).
In order to obtain more insight on the nature of CBD
binding to CB2R, saturation experiments were performed in
HEK-293T cells expressing SNAP-CB2R and using increasing
concentrations of red CB2R ligand in the presence of 10 or
100 nM CBD. Data showed that CBD decreases the affinity of
the orthosteric CB2R ligand, whereas maximum binding (Bmax)
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FIGURE 5 | Dose-response effect of CBD on ERK1/2 phosphorylation.
HEK-293T cells transfected with human CB2R were stimulated with 100 nM
of JWH133 agonist in the presence of CBD. ERK1/2 phosphorylation levels
were determined by using AlphaScreen R©SureFire R© kit. Data are normalized
and expressed as a percentage of over-basal response (mean ± SEM).
Significant differences were analyzed on data from three different experiments;
one-way ANOVA and Bonferroni’s multiple comparison post hoc test were
used for statistical analysis (F4,10 = 11, p < 0.01) (∗p < 0.05, ∗∗p < 0.01,
versus 0 nM CBD treatment).
was not modified (Figure 3A and Table 1). For comparison,
a similar experiment was performed using 10 and 100 nM
concentrations of SR144528, a CB2R antagonist that reportedly
binds to the orthosteric site (Rinaldi-Carmona et al., 1998;
Griffin et al., 1999). The KD value (Figure 3B) did not change
when this selective CB2R antagonist was used. Interestingly,
the antagonist reduced Bmax values thus suggesting that it
behaves, in binding to living cells, in an irreversible-like fashion.
Taken together, the results were suggestive of CBD binding to
an allosteric site at nanomolar concentrations while requiring
higher concentrations (in the micromolar range) to bind to the
orthosteric site.
CBD Modulates CB2R Signaling
CBD action has been often associated to CB2R expression but
its binding to the orthosteric site of the receptor is seemingly
unspecific; we hypothesized that it might act as allosteric
modulator. To test the hypothesis, we first confirmed that
the compound (concentration range: 1–1,000 nM) did not
significantly engage any G-protein-coupled signal in HEK-293T
cells expressing the human version of CB2R (Figure 4A). CBD
was also tested in cells expressing the human version of GPR55, a
GPCR that may bind cannabinoids, and the results were similar
to those in cells expressing the CB2R (Figure 4C). We next
tested whether CBD could affect the action of the selective
CB2R agonist, JWH133, on forskolin-induced intracellular cAMP
levels. The results show that the decrease in cAMP levels induced
by 100 nM JWH133 was dose-dependently blocked by CBD
(F4,71 = 15, p < 0.001) (Figure 4B). IC50 of the CBD effect
was 3 ± 0.4 nM. Again, the response of HEK-293T transiently
transfected with GPR55 to the combined treatment with CBD
and JWH133 was not significantly different than that achieved
by CBD alone (Figure 4D). Similar experiments were undertaken
but using ERK1/2 phosphorylation as a read-out. The results
in Figure 5 show that significant ERK1/2 phosphorylation
triggered by 100 nM JWH133 was dose-dependently blocked
by CBD (F4,10 = 11, p < 0.01) with an IC50 of 29 ± 0.3 nM.
These signaling data showed that CBD was able to negatively
modulate CB2R signaling at concentrations lower to those
required to significantly bind to the orthosteric center of the
receptor.
DISCUSSION
The results reported confirm that nanomolar CBD
concentrations are not able to displace the binding of WIN
55,212-2 to the orthosteric center of the CB2R in radioligand
binding assays. The binding data using the non-radioactive
homogeneous method performed in living cells showed,
however, that the binding of the fluorescent orthosteric ligand
to HEK-293T cells expressing CB2R was slightly but consistently
modified by nanomolar concentrations of CBD. The most
plausible interpretation of these data is an allosteric effect
disclosed in HTRF-mediated binding assays and a very small
difference in the binding mode of radiolabeled WIN 55,212-2
or fluorescence-labeled CM-157 to CB2R. Unfortunately, WIN
55,212-2 could not be used in non-radioactive assays as it
non-specifically interacted (for unknown reasons) with the
HTRF probes. We found the same non-specific interaction
with the fluorescent labeled CBD (data not shown). Structural
differences related to the binding of different agonists that
may be revealed by HTRF have been discussed elsewhere
(Martínez-Pinilla et al., 2016). In that paper, the extensively
studied ligand AM630 displayed a biphasic curve on competing
with CM-157 binding to CB2R. The results here presented
could fit with CBD binding to the high-affinity sites disclosed
using AM630 but not to the low-affinity ones. Alternatively,
AM630 reduction of high-affinity binding, which occurred
at subnanomolar concentrations of AM630, could be due
to the same mechanism than that of CBD. In fact, the two
compounds displayed on HTRF-based binding assays two
components, one at low concentrations, and another at higher
concentrations.
A further piece of information from results using the selective
orthosteric CB2R antagonist, SR144528, was the irreversible-like
behavior when performing HTRF-based binding to living cells.
In binding or functional assays using isolated membranes or
tissue extracts from CB2R-expressing cells, the antagonist acts
in a reversible fashion (Rinaldi-Carmona et al., 1998; Griffin
et al., 1999). CBD seemingly allosteric action was detectable
by functional experiments (cAMP and pERK1/2 assays) in
which we show that the effect of a selective CB2R agonist
was modulated by CBD at physiologically relevant (nanomolar)
concentrations. The participation of a third component, acting
as mediator of CBD effects on CB2R signaling cannot be ruled
out.
In the absence of consensus data showing a direct interaction
between CBD and cannabinoid receptors, only indirect evidence
suggests that CBD could be a modulator of endocannabinoid
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signaling. Accordingly, CBD was suspected to act as allosteric
modulator of cannabinoid receptors (Rimoldi and Bow, 2016).
In agreement with this possibility, Laprairie et al. (2015) were
the first to suggest that CBD acts as allosteric modulator
of CB1R; although no binding studies were performed, the
allosteric site in the receptor was mapped to two cysteine
residues in the N-terminal end. Therefore, CBD reduces
both potency and efficacy of endogenous and exogenous
cannabinoids on ERK1/2-PLCβ3-dependent signaling in an
heterologous expression system, and in cells endogenously
expressing the receptor. Authors also reported that CBD
affects the kinetics of β-arrestin recruitment and CB1R
internalization.
Allosteric modulators of natural origin do usually provide
negative modulation in both enzymology and pharmacology.
Allosteric action was negative in both the results reported by
Laprairie et al. (2015) on CB1R-mediated signaling and ours on
CB2R-mediated signaling; the allosteric effect in both cases seems
to be, at least in part, mediated by a CBD-induced decrease
in affinity of the orthosteric agonist (Table 1). One interesting
possibility would be that cannabinoids may produce effect of
allosteric nature on a variety of GPCRs. In support of this
option, Lane et al. (2010) showed that the endocannabinoid
2-AG acts as an allosteric modulator of the human adenosine A3
receptor. Adenosine A3 receptors are coupled to a heterotrimeric
Gi protein and the action of 2-AG resulted in a decrease
in the potency of agonists and in the basal signaling of
this adenosine receptor subtype. Their negative effects on the
receptor-mediated cAMP response are similar to those reported
here for CBD acting on CB2R. CBD is also described as an
allosteric modulator of µ- and ∂-opioid receptors (Vaysse et al.,
1987; Kathmann et al., 2006). Both 19-THC and CBD accelerate
the dissociation of opioids from the receptors although the
function of CBD on opioid receptors was not studied (Kathmann
et al., 2006).
Ligand-gated receptors are also affected by CBD. Indeed,
CBD inhibits currents mediated by serotonin 5-HT3A receptors
expressed in Xenopus laevis oocytes (Yang et al., 2010). Higher
CBD concentrations, in the micromolar range, are able to
allosterically modulate ligand-gated glycine receptors impacting
on the role of glycine in postsynaptic transmission in the
adult spinal cord (Ahrens et al., 2009; Foadi et al., 2010). The
interacting motif is mapped to Ser276 of the alpha1 subunit
of the receptor (Foadi et al., 2010), thus seemingly different
from the binding motif reported for CB1R (Laprairie et al.,
2015). Homologous residues to those in the CB1R sequence
are not present in the CB2R one and, therefore, the putative
binding site may not be located in the N-terminal domain of
the CB2R; in fact, the putative N-terminal domain is much
shorter for CB2 than for CB1 receptors (33 versus 116 amino
acids2). Elucidation of the structure for the CB1R rises hope
for a similar achievement for CB2R and, subsequently, for
detecting allosteric sites that would help in designing novel
drug discovery approaches targeting cannabinoid receptors. The
N-terminal domain of the A3 receptor is also too short to
2www.uniprot.org
be involved in the mode of action of 2-AG. Human µ and
∂ opioid receptors have longer N-terminal domains, 68 and
47, respectively, but there is no obvious homology between
them. The two cysteine residues present in the N-terminal
end of CB1R and that putatively conform a CBD binding
site are not present in the N-terminal domain of ∂-opioid
receptors. In summary, further experimental effort is needed
to identify common motives for endocannabinoid action on
ligand-gated and GPCRs, or to identify molecules interacting
with these receptors and acting as mediators of the allosteric-
like effect disclosed by CBD. Finding CBD binding motives
in cannabinoid receptors or non-GPCR CBD targets would
help in understanding some of the actions reported for
endocannabinoids and for natural cannabinoids such as THC
and CBD.
GPCRs constitute the target of 40–45% of current medicines
that act, as agonists or antagonists, via the orthosteric center.
The discovery of GPCR allosteric modulators or of modulators
of signaling at concentrations 1–2 orders of magnitude below
the IC50 values obtained in competing with the binding of
orthosteric compounds, opens new perspectives for therapeutic
benefit.
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